Attached To Antigen Or Hapten; Derivative Thereof Patents (Class 424/1.57)
  • Patent number: 11034739
    Abstract: Disclosed are conjugates and compositions comprising an amyloid beta binding protein conjugated to a MerTK ligand. Disclosed are methods of clearing amyloid beta aggregates from a subject comprising administering a therapeutically effective amount of the conjugates and compositions comprising an amyloid beta binding protein conjugated to a MerTK ligand. Disclosed are methods of treating Alzheimer's Disease comprising administering to a subject in need thereof a therapeutically effective amount of conjugates and compositions comprising an amyloid beta binding protein conjugated to a MerTK ligand.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: June 15, 2021
    Assignee: The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University of Nevada
    Inventor: Nora Blanca Caberoy
  • Patent number: 10035831
    Abstract: The invention provides an A? peptide aggregation inhibitor, an A? peptide toxicity reducing agent, and a preventive and/or therapeutic agent for Alzheimer's disease. The oxidized A? peptide in which one or more amino acid residues of A? peptide have been oxidized (excluding an oxidized A? peptide in which only Met has been oxidized).
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: July 31, 2018
    Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Motomu Kanai, Yohei Soma, Atsuhiko Taniguchi, Daisuke Sasaki
  • Patent number: 10029014
    Abstract: The present disclosure relates to a dendrimer-based conjugate of the formula Vm-D-C-D?-(T-F)n, which is useful for tumor targeting drug delivery. The use of asymmetric dendrimers allow for specific targeting as well as synthetic reproducibility.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: July 24, 2018
    Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Iwao Ojima, Tao Wang, Yu-Han Teng
  • Patent number: 9849165
    Abstract: A novel constrained peptide epitope derived from A?, related antibody compositions and methods of use. An isolated antibody that specifically binds to a cyclic peptide comprising the conformational epitope corresponding to a solvent-exposed, antibody accessible knuckle region of oligomeric A? is described. An antigenic peptide comprising an epitope having a constrained cyclic configuration, corresponding to a solvent-exposed, antibody accessible knuckle region of oligomeric A? is also described. Methods of treating, preventing, and diagnosing Alzheimer's disease are also described.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: December 26, 2017
    Assignee: The University of British Columbia
    Inventor: Neil R. Cashman
  • Patent number: 9364486
    Abstract: Disclosed is a method of remyelinating axons with 6-substituted estradiol compounds of the formula The methods can be used to treat a variety of demyelinating diseases.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: June 14, 2016
    Assignee: Endece LLC
    Inventors: James G. Yarger, Steve Nye
  • Patent number: 8889142
    Abstract: The present invention is related to antigen from Chlamydia trachomatis which are recognized by specific antibodies from individuals infected with Chlamydia or which can induce T cells from the same individuals to secrete gamma-interferon. The T cell reactive antigens are present in a whole-cell lysate and have apparent molecular weights of 5-12, 16-20, 25-35 and 58-74 kDa as determined by SDS-PAGE. The antigens of the invention are believed to be useful in vaccines but also as diagnostic compositions.
    Type: Grant
    Filed: October 11, 2005
    Date of Patent: November 18, 2014
    Assignee: Statens Serum Institut
    Inventors: Michael Theisen, Anja Olsen, Robert Leah, Frank Follmann, Klaus Jensen, Peter Andersen
  • Patent number: 8815255
    Abstract: The present invention relates to combination vaccines and/or the combined use of immunogenic compositions for the treatment and/or prophylaxis of cattle against microbiological infections, wherein the infections are caused by M. bovis and at least one further cattle relevant pathogen. The combination vaccine as described herein comprises at least one M. bovis antigen, preferably the attenuated, avirulent M. bovis as provided herewith and one or more further immunologically active components effective for the treatment and/or prophylaxis of infections caused by a further pathogen of cattle.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: August 26, 2014
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Michael Beck, Phillip Wayne Hayes, Jeffrey P. Knittel
  • Publication number: 20140086832
    Abstract: The present invention relates to methods and compositions for pretargeting delivery of therapeutic agents. In preferred embodiments, the pretargeting method comprises: a) administering a bispecific antibody with a first binding site for a disease-associated antigen and a hapten on a targetable construct; b) administering a targetable construct comprising at least one therapeutic agent. In preferred embodiments, the bispecific antibody is made by the dock-and-lock (DNL) technique. In a more preferred embodiment, the targetable construct comprises one or more SN-38 moieties.
    Type: Application
    Filed: November 7, 2013
    Publication date: March 27, 2014
    Applicant: Immunomedics, Inc.
    Inventors: William J. McBride, Christopher A. D'Souza, Chien-Hsing Chang, David M. Goldenberg
  • Patent number: 8647636
    Abstract: Disclosed are compositions, kits, and methods for inducing an immune response against disease. The dosage of antigen contained or utilized in the presently disclosed compositions, kits, and methods is substantially lower than dosages conventionally used in the field. The compositions, kits, and methods may be utilized to induce a cell-mediated response, such as a T-helper cell response, and/or a humoral response against a pathogen or a disease. In some embodiments, the compositions, kits, and methods may be utilized to induce preferentially a Th1 response versus other types of immune responses such as a Th2 response.
    Type: Grant
    Filed: September 4, 2012
    Date of Patent: February 11, 2014
    Assignee: Auburn University
    Inventors: Yihang Li, Erfan Ullah Chowdhury, Bernhard Kaltenboeck
  • Patent number: 8540964
    Abstract: This invention provides a polyvalent vaccine comprising at least two conjugated antigens selected from a group containing glycolipid antigen, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant. This invention also provides a multivalent vaccine comprising at least two of the following: glycosylated MUC-1-32mer, Globo H, GM2, Ley, Tn(c), sTN(c), and TF(c). This invention provides the vaccine above, wherein the adjuvant is saponin-based adjuvant. This invention provides a method for inducing immune response in a subject comprising administering an effective amount of the vaccine above to the subject. Finally, this invention provides a method for treating cancer in a subject comprising administering an appropriate amount of the vaccine above to the subject.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: September 24, 2013
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Philip O. Livingston, Govindaswami Ragupathi, Samuel J. Danishefsky
  • Patent number: 8333996
    Abstract: An improved calcium phosphate delivery vehicle or adjuvant with incorporated adjuvanticity enhancing means and methods of producing same are disclosed. The adjuvant can be fabricated to desired formulations as appropriate and based on the intended purpose. Particle sizes can be adjusted to enhance adjuvant activity. Other supplemental materials may be added as desired and in appropriate proportions to selectively elicit preferred components of the immune system and to enhance the adjuvant's effect on the host response.
    Type: Grant
    Filed: September 15, 1998
    Date of Patent: December 18, 2012
    Assignee: Etex Corporation
    Inventors: D. Duke Lee, Maria Aiolova
  • Patent number: 8303960
    Abstract: The invention provides a radiolabeled affibody molecule comprising a fragment of an IgG-binding domain of protein A from Staphylococcus aureus, a bifunctional linker, and a radiolabel comprising 18F or 76Br, wherein the bifunctional linker links the fragment and the radiolabel. The affibody molecule binds with high affinity to select receptors, which are over-expressed in certain cancers. Since the radionuclides emit a positron, the in vitro and in vivo binding characteristics of the radiolabeled affibody can be assessed using diagnostic imaging.
    Type: Grant
    Filed: February 27, 2008
    Date of Patent: November 6, 2012
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jacek Capala, Dale O. Kiesewetter, Gabriela Kramer-Marek, Sang Bong Lee
  • Publication number: 20120156131
    Abstract: The present invention is directed to methods and compositions for the treatment and diagnosis of neuroectodermally-derived tumors, such as gliomas. The inventive methods of treatment generally include local (e.g., intracavitary) administration of a chloroxotoxin moiety conjugated to a cytotoxic moiety to a patient. Also provided are diagnostic methods for screening neoplastic neuroectodermal tumors.
    Type: Application
    Filed: June 14, 2011
    Publication date: June 21, 2012
    Applicant: MORPHOTEK, INC.
    Inventor: Vernon Leon Alvarez
  • Patent number: 8114381
    Abstract: Positron emitting compounds and methods of their production are provided. The compounds have the formula: (F)m G (R)n wherein each R is a group comprising at least one carbon, nitrogen, phosphorus or sulfur atom and G is joined to R through said carbon, nitrogen, phosphorus or sulfur atom; G is silicon or boron; m is 2 to 5 and n is 1 to 3 with m+n=3 to 6 when G is silicon; m is 1 to 3 and n is 1 to 3 with m+n=3 to 4 when G is boron; and wherein the compound further comprises one or more counterions when the above formula is charged; and wherein at least one F is 18F.
    Type: Grant
    Filed: February 14, 2005
    Date of Patent: February 14, 2012
    Assignee: The University of British Columbia
    Inventors: David M. Perrin, Richard Ting
  • Patent number: 8110196
    Abstract: The present invention relates to therapeutic and prophylactic methods for treating or preventing an infectious disease in a subject by stimulating or enhancing an immune response against an infectious agent causing the disease. The methods comprise administering to the subject a plurality of compositions, each composition being administered to a different site of the subject, wherein each site is, or substantially drains to, an anatomically distinct lymph node, a group of lymph nodes, a nonencapsulated cluster of lymphoid tissue, or the spleen. Each composition comprises at least one antigenic molecule having one or more epitopes of the same infectious agent or a strain thereof. The antigenic molecules of each composition comprise in aggregate a set of epitopes distinct from that of any other composition that is administered to the subject.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: February 7, 2012
    Assignee: Polytopas LLC
    Inventors: Michael W. Deem, Jeong-Man Park, Hao Zhou
  • Patent number: 8092780
    Abstract: This invention provides a polyvalent vaccine comprising at least two conjugated antigens selected from a group containing glycolipid antigen, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant. This invention also provides a multivalent vaccine comprising at least two of the following: glycosylated MUC-1-32mer, Globo H, GM2, Ley, Tn(c), sTN(c), and TF(c). This invention provides the vaccine above, wherein the adjuvant is saponin-based adjuvant. This invention provides a method for inducing immune response in a subject comprising administering an effective amount of the vaccine above to the subject. Finally, this invention provides a method for treating cancer in a subject comprising administering an appropriate amount of the vaccine above to the subject.
    Type: Grant
    Filed: October 31, 2008
    Date of Patent: January 10, 2012
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Philip O. Livingston, Govindaswami Ragupathi, Samuel J. Danishefsky
  • Publication number: 20110318264
    Abstract: The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of colorectal, in particular colonic, and gastric tumor tissues and colorectal, in particular colonic, and gastric tissues, and which represent targets for therapy or diagnosis of such tumor diseases in a subject.
    Type: Application
    Filed: February 18, 2010
    Publication date: December 29, 2011
    Inventors: Ugur Sahin, Özlem Türecl, Michael Koslowski
  • Patent number: 8034351
    Abstract: The present invention provides compositions and methods for augmenting vaccine immunogenicity using mucin-immunoglobulin fusion proteins.
    Type: Grant
    Filed: April 22, 2003
    Date of Patent: October 11, 2011
    Assignee: Recopharma AB
    Inventor: Jan Holgersson
  • Patent number: 7927612
    Abstract: Methods for treating neoplasms, tumors and cancers, using one or more haptens and coagulation agents or treatments, alone or in combination with other anti-neoplastic agents or treatments, are provided. Also provided are combinations, and kits containing the combinations for effecting the therapy.
    Type: Grant
    Filed: October 25, 2004
    Date of Patent: April 19, 2011
    Inventor: Baofa Yu
  • Publication number: 20110076233
    Abstract: The present invention relates to methods and compositions for pretargeting delivery of therapeutic agents. In preferred embodiments, the pretargeting method comprises: a) administering a bispecific antibody with a first binding site for a disease-associated antigen and a hapten on a targetable construct; b) administering a targetable construct comprising at least one therapeutic agent. In preferred embodiments, the bispecific antibody is made by the dock-and-lock (DNL) technique. In a more preferred embodiment, the targetable construct comprises one or more SN-38 moieties.
    Type: Application
    Filed: December 9, 2010
    Publication date: March 31, 2011
    Applicant: IMMUNOMEDICS, INC.
    Inventors: William J. McBride, Christopher A. D'Souza, Chien-Hsing Chang, David M. Goldenberg
  • Patent number: 7807377
    Abstract: The present invention concerns artificial antigen presenting cells (aAPCs) and methods of making and using the same, for example, to isolate, identify, and expand T cell populations specifically reactive against a disease-associated antigenic peptide, as well as to modulate responses of antigen-specific T cells both in vivo, ex vivo, and in vitro. Accordingly, the aAPCs of the invention can be used to treat conditions that would benefit from modulation of a T cell response, for example, autoimmune disorders, allergies, cancers, viral infections, and graft rejection. In certain preferred embodiments, the aAPCs are liposomes comprised of MHC:peptide complexes and accessory molecules. Other molecules, such as co-stimulatory molecules and adhesion molecules, can also be included in the compositions of the invention. In other embodiments, the aAPCs are comprised of a scaffold to which a plurality of MHC:peptide complexes and accessory molecules (as well as other molecules) can be attached at high density.
    Type: Grant
    Filed: October 6, 2004
    Date of Patent: October 5, 2010
    Inventor: Salvatore Albani
  • Publication number: 20100172833
    Abstract: Methods for the diagnosis of hepatocellular carcinoma (HCC) are set forth. Improved assay methods and scanning methods are included that employ non-cell-associated and cell-associated HCC related proteins. Such methods are based upon the discovery of genes that were up-regulated in diseased versus normal tissue as well as in HCC tissue when compared to the tissue of patients with other ailments.
    Type: Application
    Filed: August 7, 2009
    Publication date: July 8, 2010
    Applicants: ILLUMIGEN BIOSCIENCES, INC., UNIVERSITY OF WASHINGTON
    Inventors: Michael Katze, Roger Bumgarner, Mariya Smit, Gary Rosenberg
  • Patent number: 7641891
    Abstract: The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: January 5, 2010
    Assignee: Immunomedics, Inc.
    Inventors: Hans J. Hansen, David M. Goldenberg
  • Patent number: 7611711
    Abstract: The present invention relates to the diagnosis, evaluation, and therapeutic intervention of disorders mediated by the activity of cell surface receptor VEGFR-3, which activity often is stimulated by VEGFR-3 ligands VEGF-C and VEGF-D. More particularly, the present invention identifies novel methods and compositions for the inhibition of VEGF-C/D binding to VEGFR-3. The compositions of the present invention will be useful in the inhibition of angiogenesis and lymphangiogenesis.
    Type: Grant
    Filed: January 15, 2002
    Date of Patent: November 3, 2009
    Assignee: Vegenics Limited
    Inventors: Kari Alitalo, Erkki Koivunen, Hajime Kubo
  • Patent number: 7608269
    Abstract: An alternative HER-2/neu product, herstatin, consists of subdomains I and II from the ectodomain of p185HER-2 and a unique 79 amino acid C-terminus encoded by intron 8. Recombinant herstatin added to cells was found to bind to and inhibit p185HER-2. The effects of ectopic expression of herstatin in combination with either p185HER-2 or with its homolog, the EGF receptor, in several cell lines was studied. Cotransfection of herstatin with HER-2 inhibited p185HER-2 levels and caused an approximate 8-fold reduction in p185 tyrosine phosphorylation. Inhibition of p185HER-2 tyrosine phosphorylation corresponded to a dramatic decline in colony formation by cells that coexpressed p185HER-2 and herstatin. Herstatin also interferred with EGF activation of the EGF receptor in cotransfected cells as demonstrated by impaired receptor tyrosine phosphorylation, reduced receptor down-regulation, and growth suppression.
    Type: Grant
    Filed: August 14, 2001
    Date of Patent: October 27, 2009
    Assignee: Oregon Health and Science University
    Inventor: Gail M. Clinton
  • Patent number: 7598047
    Abstract: A process and a kit are provided for detecting differences in two or more samples of protein, including proteins bearing post-translational modifications and peptides. Proteins are prepared, for example, from each of a different group of cell samples or body fluid samples to be compared. Each protein extract is labeled with a different one of a luminescent dye from a matched set of dyes. The matched dyes have generally the same ionic and pH characteristics but emit light at different wavelengths to exhibit a different color upon luminescence detection. The labeled protein extracts are mixed together and separated together by electrophoresis or a chromatographic method. The separation is observed to detect proteins unique to one sample or present in a greater ratio in one sample than in the other. Those unique or excess proteins will fluoresce the color of one of the dyes used. Proteins common to each sample migrate together and fluoresce the same.
    Type: Grant
    Filed: November 14, 2003
    Date of Patent: October 6, 2009
    Assignee: Carnegie Mellon University
    Inventors: Jonathan Minden, Alan Waggoner, Susan Janet Fowler
  • Patent number: 7585509
    Abstract: The ErbB-2 receptor, a member of the tyrosine kinase type 1 family of receptors, has been implicated in many human malignancies. Bacteriophage display technology was employed to identify peptides that bound to the extracellular domain of human ErbB-2. The peptide KCCYSL, most frequently occurring in the affinity selected population, was chemically synthesized and characterized for its binding activities to the recombinant extracellular domain of ErbB-2. The synthetic peptide exhibits high specificity to ErbB-2 as well as to ErbB-1, another member of ErbB family. Thus, this peptide can be employed in cancer imaging or therapeutic agent targeting to malignant cells ErbB-2 receptor.
    Type: Grant
    Filed: July 3, 2003
    Date of Patent: September 8, 2009
    Assignee: The Curators of The University of Missouri
    Inventors: Thomas P. Quinn, Natalia G. Karasseva
  • Patent number: 7521432
    Abstract: Novel compositions and methods are provided for identifying agents which affect chromosomal stability and aging.
    Type: Grant
    Filed: April 25, 2007
    Date of Patent: April 21, 2009
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: John M. Denu, Kirk G. Tanner
  • Patent number: 7479266
    Abstract: This invention provides a polyvalent vaccine comprising at least two conjugated antigens selected from a group containing glycolipid antigen, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant. This invention also provides a multivalent vaccine comprising at least two of the following: glycosylated MUC-1-32mer, Globo H, GM2, Ley, Tn(c), sTN(c), and TF(c). This invention provides the vaccine above, wherein the adjuvant is saponin-based adjuvant. This invention provides a method for inducing immune response in a subject comprising administering an effective amount of the vaccine above to the subject. Finally, this invention provides a method for treating cancer in a subject comprising administering an appropriate amount of the vaccine above to the subject.
    Type: Grant
    Filed: January 6, 2004
    Date of Patent: January 20, 2009
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Philip O. Livingston, Govindaswami Ragupathi, Samuel J. Danishefsky
  • Publication number: 20080311035
    Abstract: New diagnostic agents for positron emission tomography (PET) and methods for use of such agents for imaging of human or animal tissue are described, wherein a primary active component of such agents is a radiolabeled halogenated xanthene or halogenated xanthene derivative. Preferably, the radiolabeled halogenated xanthene is radiolabeled Rose Bengal or a functional derivative of Rose Bengal.
    Type: Application
    Filed: August 19, 2008
    Publication date: December 18, 2008
    Inventors: Timothy C. Scott, H. Craig Dees, Eric A. Wachter
  • Patent number: 7402299
    Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection.
    Type: Grant
    Filed: November 30, 2004
    Date of Patent: July 22, 2008
    Assignee: Provectus Pharmatech, Inc.
    Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
  • Patent number: 7387772
    Abstract: The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: June 17, 2008
    Assignee: Immunimedics, Inc.
    Inventors: Hans J. Hansen, David M. Goldenberg
  • Patent number: 7384623
    Abstract: High energy phototherapeutic agents or radiosensitizer agents comprised of a halogenated xanthene, or other related agents that exhibit a preference for concentration in biologically sensitive structures in diseased tissue, and methods of treating and imaging using such radiosensitizer agents in such diseased tissue are described herein.
    Type: Grant
    Filed: August 25, 1999
    Date of Patent: June 10, 2008
    Assignee: Provectus Pharmatech, Inc.
    Inventors: H. Craig Dees, Timothy Scott, John T. Smolik, Eric A. Wachter
  • Patent number: 7374765
    Abstract: Methods and compositions are provided for the diagnosis and treatment of iron misregulation diseases, including HFE polypeptides, agonists, and antagonists, and transferrin receptor agonists and antagonists.
    Type: Grant
    Filed: October 1, 2004
    Date of Patent: May 20, 2008
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: John N. Feder, Randall C. Schatzman, Zenta Tsuchihashi
  • Patent number: 7342091
    Abstract: The invention concerns a peptide having the biological activity of an inhibitor of amyloid formation and its diagnostic and medical use.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: March 11, 2008
    Assignee: Fraunhofer-Gesellschaf zur Forderung der angewandten Forschung e.V
    Inventors: Afroditi Kapurniotu, Jürgen Bernhagen, Herwig Brunner
  • Publication number: 20080038191
    Abstract: Positron emitting compounds and methods of their production are provided. The compounds have the formula: (F)m G (R)n wherein each R is a group comprising at least one carbon, nitrogen, phosphorus or sulfur atom and G is joined to R through said carbon, nitrogen, phosphorus or sulfur atom; G is silicon or boron; m is 2 to 5 and n is 1 to 3 with m+n=3 to 6 when G is silicon; m is 1 to 3 and n is 1 to 3 with m+n=3 to 4 when G is boron; and wherein the compound further comprises one or more counterions when the above formula is charged; and wherein at least one F is 18 F.
    Type: Application
    Filed: February 14, 2005
    Publication date: February 14, 2008
    Inventors: David M. Perrin, Richard Ting
  • Patent number: 7312461
    Abstract: A laparoscopic tumor therapy method and an articulated electron beam transport system are provided for use with a high power, long focus electron source for tumor therapy. The high power, long focus electron source generates an e-beam. The e-beam is transported through a laparoscopic tube proximate a target tumor for electron irradiation therapy.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: December 25, 2007
    Assignee: UChicago Argonne LLC
    Inventors: John W. Lewellen, John Noonan
  • Patent number: 7291606
    Abstract: Novel compositions and methods are provided for identifying agents which affect chromosomal stability and aging.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: November 6, 2007
    Assignee: Wisconson Alumni Research Foundation
    Inventors: John M. Denu, Kirk G. Tanner
  • Patent number: 7201890
    Abstract: Methods are provided for close-range intraoperative, endoscopic and intravascular detection and treatment of lesions, including tumors and non-malignant lesions. The methods use antibody fragments or subfragments labeled with isotopic and non-isotopic agents. Also provided are methods for detection and treatment of lesions with photodynamic agents and methods of treating lesions with a protein conjugated to an agent capable of being activated to emit Auger electron or other ionizing radiation. Compositions and kits useful in the above methods are also provided.
    Type: Grant
    Filed: March 4, 2002
    Date of Patent: April 10, 2007
    Assignee: Immunomedics, Inc.
    Inventor: Milton D. Goldenberg
  • Patent number: 7045503
    Abstract: Novel metal binding ligands are disclosed that may be coupled to peptides for use in methods of diagnosis and therapy. Peptides containing the ligands are produced using a method wherein ligand introduction or cyclization can be conducted at any point during the synthesis of the peptide. Such peptide derivatives are readily labeled with radiometals, such as isotopes of rhenium or technetium, while retaining their ability to tightly bind specific peptide receptors.
    Type: Grant
    Filed: October 2, 2000
    Date of Patent: May 16, 2006
    Assignee: Immunomedics, Inc.
    Inventors: William J. McBride, Gary L. Griffiths
  • Patent number: 7022483
    Abstract: The present invention is directed to methods for the identification and isolation of antigen-specific T cells using a novel class of artificial antigen presenting cells. The resulting T cells may be used to produce expanded T cell populations as well as for modulating T cell responses. In general, the artificial antigen presenting cells useful in such methods are liposomes that contain MHC:peptide complexes presented on the outer surface of the liposome. Such artificial antigen presenting cells may also include accessory molecules, co-stimulatory molecules, adhesion molecules, and other molecules irrelevant to T cell binding or modulation that are used in the binding of artificial antigen presenting cells to solid support systems that may be used in the retrieval and identification of antigen-specific T cells.
    Type: Grant
    Filed: October 19, 1999
    Date of Patent: April 4, 2006
    Inventor: Salvatore Albani
  • Patent number: 7015306
    Abstract: Peptide analogs of neurotensin are disclosed which are resistant to enzymatic degradation and which retain high binding affinity for neurotensin receptors. Pharmaceutical compositions of these compounds are useful for diagnostic and therapeutic purposes.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: March 21, 2006
    Assignee: BioSynthema, Inc.
    Inventors: Ananthachari Srinivasan, Jack L. Erion, Michelle A. Schmidt
  • Patent number: 6982084
    Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.
    Type: Grant
    Filed: March 31, 2004
    Date of Patent: January 3, 2006
    Assignee: NeuraLab Limited
    Inventor: Dale B. Schenk
  • Patent number: 6972127
    Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.
    Type: Grant
    Filed: September 2, 2004
    Date of Patent: December 6, 2005
    Assignee: Neuralab Limited
    Inventor: Dale B. Schenk
  • Patent number: 6962707
    Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A? peptide or an antibody thereto.
    Type: Grant
    Filed: July 1, 2004
    Date of Patent: November 8, 2005
    Assignee: Neuralab Limited
    Inventor: Dale B. Schenk
  • Patent number: 6946135
    Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A?, peptide or an antibody thereto.
    Type: Grant
    Filed: September 2, 2004
    Date of Patent: September 20, 2005
    Assignee: Neuralab Limited
    Inventor: Dale B. Schenk
  • Patent number: 6913767
    Abstract: Methods and compositions are provided for the encapsulation of antigens in PLGA microspheres for use as vaccines. Such microspheres can also contain adjuvants. Mixtures of microspheres are provided which release antigen at desired intervals to provide boosts with antigen.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: July 5, 2005
    Assignee: Genentech, Inc.
    Inventors: Jeffrey L. Cleland, Amy Lim, Michael Frank Powell
  • Patent number: 6844425
    Abstract: The invention relates to molecules for treatment and diagnosis of tumors and malignancies, comprising a tumor seeking biomolecule, which is coupled to an intercalating moiety, which is capable of complexing a metal, which metal is preferably a radioactive metal, to the use of these molecules and to therapeutic and diagnostic compositions containing them.
    Type: Grant
    Filed: February 24, 2000
    Date of Patent: January 18, 2005
    Assignee: Mallinckrodt Inc.
    Inventors: Roger Ariel Alberto, Pascal Jean-Marie Hafliger
  • Patent number: 6787140
    Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A&bgr; peptide or an antibody thereto.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: September 7, 2004
    Assignee: Neuralab Limited
    Inventor: Dale B. Schenk
  • Patent number: 6787138
    Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A&bgr; peptide or an antibody thereto.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: September 7, 2004
    Assignee: Neuralab Limited
    Inventor: Dale B. Schenk